CY1113290T1 - Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3 - Google Patents

Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3

Info

Publication number
CY1113290T1
CY1113290T1 CY20121100908T CY121100908T CY1113290T1 CY 1113290 T1 CY1113290 T1 CY 1113290T1 CY 20121100908 T CY20121100908 T CY 20121100908T CY 121100908 T CY121100908 T CY 121100908T CY 1113290 T1 CY1113290 T1 CY 1113290T1
Authority
CY
Cyprus
Prior art keywords
mag
detectors
diagnosis
indicator
cancer detection
Prior art date
Application number
CY20121100908T
Other languages
Greek (el)
English (en)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne-Marie Beer
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1113290T1 publication Critical patent/CY1113290T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CY20121100908T 2006-06-21 2012-10-02 Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3 CY1113290T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
EP07786793A EP2041308B1 (fr) 2006-06-21 2007-06-21 Procédé de diagnostic et traitement anticancéreux

Publications (1)

Publication Number Publication Date
CY1113290T1 true CY1113290T1 (el) 2016-04-13

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100908T CY1113290T1 (el) 2006-06-21 2012-10-02 Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3

Country Status (28)

Country Link
US (1) US8936919B2 (fr)
EP (1) EP2041308B1 (fr)
JP (2) JP2009540812A (fr)
KR (1) KR101455589B1 (fr)
CN (1) CN101506383B (fr)
AU (1) AU2007263019B2 (fr)
BR (1) BRPI0713599A2 (fr)
CA (1) CA2656909A1 (fr)
CO (1) CO6140072A2 (fr)
CY (1) CY1113290T1 (fr)
DK (1) DK2041308T3 (fr)
EA (1) EA016347B1 (fr)
ES (1) ES2389513T3 (fr)
GB (1) GB0612342D0 (fr)
HK (1) HK1127627A1 (fr)
HR (1) HRP20120761T1 (fr)
IL (1) IL195975A (fr)
MA (1) MA30565B1 (fr)
MX (1) MX2008016493A (fr)
MY (1) MY147511A (fr)
NO (1) NO20085290L (fr)
NZ (1) NZ573809A (fr)
PL (1) PL2041308T3 (fr)
PT (1) PT2041308E (fr)
SI (1) SI2041308T1 (fr)
UA (1) UA95956C2 (fr)
WO (1) WO2007147876A2 (fr)
ZA (1) ZA200810695B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932723B (zh) 2007-09-17 2014-09-10 肿瘤甲基化科学公司 改进的对mage-a表达的检测
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
DE69524264T2 (de) * 1994-03-01 2002-07-18 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
DK1659178T3 (da) * 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
US6710172B1 (en) 1998-10-02 2004-03-23 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
WO2003045427A2 (fr) * 2001-11-29 2003-06-05 Dandrit Biotech A/S Composition pharmaceutique servant a induire une reponse immune chez l'homme ou chez l'animal
DK1572105T3 (da) * 2002-11-14 2011-10-17 Wayne John Cancer Inst Detektion af mikrometastase af melamoner og brystcancer i paraffinindlejret tumor drænende lymfeknuder ved hjælp af kvantitativ multimaker RT-PCR
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
MA30565B1 (fr) 2009-07-01
ZA200810695B (en) 2014-03-26
KR20090034900A (ko) 2009-04-08
BRPI0713599A2 (pt) 2012-11-06
GB0612342D0 (en) 2006-08-02
KR101455589B1 (ko) 2014-10-28
AU2007263019B2 (en) 2012-11-08
ES2389513T3 (es) 2012-10-26
EP2041308B1 (fr) 2012-07-11
EA200802356A1 (ru) 2009-06-30
UA95956C2 (uk) 2011-09-26
AU2007263019A1 (en) 2007-12-27
WO2007147876A2 (fr) 2007-12-27
IL195975A0 (en) 2009-09-01
EP2041308A2 (fr) 2009-04-01
US20120040341A1 (en) 2012-02-16
IL195975A (en) 2012-08-30
CN101506383A (zh) 2009-08-12
HRP20120761T1 (hr) 2012-10-31
MX2008016493A (es) 2009-05-21
MY147511A (en) 2012-12-31
JP5705191B2 (ja) 2015-04-22
NO20085290L (no) 2009-01-19
JP2009540812A (ja) 2009-11-26
CO6140072A2 (es) 2010-03-19
CN101506383B (zh) 2013-08-28
CA2656909A1 (fr) 2007-12-27
PL2041308T3 (pl) 2012-11-30
PT2041308E (pt) 2012-10-09
WO2007147876A3 (fr) 2008-05-15
HK1127627A1 (en) 2009-10-02
SI2041308T1 (sl) 2012-10-30
NZ573809A (en) 2011-12-22
JP2013046630A (ja) 2013-03-07
US8936919B2 (en) 2015-01-20
EA016347B1 (ru) 2012-04-30
DK2041308T3 (da) 2012-10-08

Similar Documents

Publication Publication Date Title
JP2009538607A5 (fr)
MX2007004176A (es) B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
CY1122871T1 (el) Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1
WO2014140933A8 (fr) Procédé de pronostic et de traitement de métastases cancéreuses
GB201009641D0 (en) Methods of monitoring conditions by sequence analysis
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
NZ599194A (en) Methods to predict clinical outcome of cancer
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
CY1116089T1 (el) Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων
WO2010027903A8 (fr) Diagnostic du cancer du poumon
CY1116133T1 (el) Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσης
EP4293358A3 (fr) Composés organique volatiles utilisé comme biomarqueurs du cancer
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
ES2570627T3 (es) Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
CY1112322T1 (el) Παραγωγα σπειρο(5.5)ενδεκανιου
CY1119653T1 (el) Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης
CY1113290T1 (el) Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
EP1899726A4 (fr) Méthodes de diagnostic et de traitement des événements cérébrovasculaires reposant sur des peptides nr2
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
DE602006018458D1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании